NRC Health Q2 2025: TRCV grows 2% sequentially; net margin 0% on exec comp; adj EBITDA margin 30%

NRC HEALTH

2025-Q2 EPS reported $0.25 revenue$67,588,000

TRCV grew 2% sequentially, third consecutive quarter of growth and highest since Q1 2021.
Net margin 0% due to non-recurring executive compensation; adjusted EBITDA margin 30%.
Declared $0.12 quarterly dividend; payable Oct 10, 2025 to holders of record Sept 26, 2025.
Repurchased 381,736 shares at $14.96 avg in Q2; $16.1M returned to shareholders YTD.
New CEO Trent Green reinstated quarterly earnings call; cites strong customer feedback.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.